CONTEXT: The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure commonly used to screen for symptoms of anxiety and depression in cancer patients. The HADS has demonstrated validity in over 100 languages, including Spanish. However, validation studies have largely used European Spanish-speaking samples with a variety of medical diagnoses. OBJECTIVES: The aim of this study was to examine the psychometric properties of the Spanish version of the HADS in a sample of Spanish-speaking Latina women with cancer in the U.S. METHODS: Participants (N = 242) completed self-report measures of anxiety and depression (HADS), quality of life (Functional Assessment of Cancer Therapy-General Version), cancer-related distress (Impact of Events Scale-Revised Version Intrusion Subscale), and cancer symptomatology (Memorial Symptom Assessment Scale-Short Form) before initiating chemotherapy and five to seven weeks later. Analyses evaluated internal consistency and test-retest reliability, construct validity, and convergent validity. RESULTS: Factor analysis supported a two-factor structure as proposed by the original HADS developers (X2 [76, N = 242] = 143.3, P < 0.001, comparative fit index = 0.94, root-mean-square error of approximation = 0.06, and standardized root-mean-square residual = 0.06). The HADS and its subscales demonstrated good internal consistency (α = 0.83-0.88) and test-retest reliability (intraclass correlation coefficient = 0.76-0.82). Construct validity was evidenced by factor analysis and item-subscale, item-total, and subscale-total correlations. Convergent validity was demonstrated by strong positive correlations with cancer-related distress (r = 0.51-0.71) and symptom severity (r = 0.54-0.62) and strong negative correlations with quality of life (r = -0.63 to -0.76) (all P's < 0.001). CONCLUSION: The Spanish version of the HADS evidenced sound psychometric properties in Latinas with cancer in the U.S., supporting its use in clinical oncology research and practice.
CONTEXT: The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure commonly used to screen for symptoms of anxiety and depression in cancerpatients. The HADS has demonstrated validity in over 100 languages, including Spanish. However, validation studies have largely used European Spanish-speaking samples with a variety of medical diagnoses. OBJECTIVES: The aim of this study was to examine the psychometric properties of the Spanish version of the HADS in a sample of Spanish-speaking Latina women with cancer in the U.S. METHODS:Participants (N = 242) completed self-report measures of anxiety and depression (HADS), quality of life (Functional Assessment of Cancer Therapy-General Version), cancer-related distress (Impact of Events Scale-Revised Version Intrusion Subscale), and cancer symptomatology (Memorial Symptom Assessment Scale-Short Form) before initiating chemotherapy and five to seven weeks later. Analyses evaluated internal consistency and test-retest reliability, construct validity, and convergent validity. RESULTS: Factor analysis supported a two-factor structure as proposed by the original HADS developers (X2 [76, N = 242] = 143.3, P < 0.001, comparative fit index = 0.94, root-mean-square error of approximation = 0.06, and standardized root-mean-square residual = 0.06). The HADS and its subscales demonstrated good internal consistency (α = 0.83-0.88) and test-retest reliability (intraclass correlation coefficient = 0.76-0.82). Construct validity was evidenced by factor analysis and item-subscale, item-total, and subscale-total correlations. Convergent validity was demonstrated by strong positive correlations with cancer-related distress (r = 0.51-0.71) and symptom severity (r = 0.54-0.62) and strong negative correlations with quality of life (r = -0.63 to -0.76) (all P's < 0.001). CONCLUSION: The Spanish version of the HADS evidenced sound psychometric properties in Latinas with cancer in the U.S., supporting its use in clinical oncology research and practice.
Authors: J J Dapueto; C Francolino; I Gotta; R Levin; I Alonso; E Barrios; Y Afonzo; S Cambiasso Journal: Psychooncology Date: 2001 Jan-Feb Impact factor: 3.894
Authors: Morgan S Lee; Dinorah Martinez Tyson; Brian D Gonzalez; Brent J Small; Suzanne C Lechner; Michael H Antoni; Andrea Vinard; Madeline Krause; Cathy Meade; Paul B Jacobsen Journal: Psychooncology Date: 2017-07-13 Impact factor: 3.894
Authors: Mark T Hegel; Caroline P Moore; E Dale Collins; Stephen Kearing; Karen L Gillock; Raine L Riggs; Kate F Clay; Tim A Ahles Journal: Cancer Date: 2006-12-15 Impact factor: 6.860
Authors: Adam B Smith; Peter J Selby; Galina Velikova; Dan Stark; E Penny Wright; Ann Gould; Ann Cull Journal: Psychol Psychother Date: 2002-06 Impact factor: 3.915
Authors: Elisabeth L Zeilinger; Ingo W Nader; Wolfgang Wiedermann; Mencia R Gutierrez-Colosia; Matthias Unseld; Simone Lubowitzki; Markus Raderer; Philipp B Staber; Peter Valent; Alexander Gaiger Journal: Int J Clin Health Psychol Date: 2022-05-26
Authors: Ana Soto-Rubio; Selene Valero-Moreno; José Luis Díaz; Yolanda Andreu; Marián Pérez-Marín Journal: PLoS One Date: 2020-10-16 Impact factor: 3.240
Authors: Eida M Castro-Figueroa; Normarie Torres-Blasco; Milagros C Rosal; Julio C Jiménez; Wallesca P Castro-Rodríguez; Marilis González-Lorenzo; Héctor Vélez-Cortés; Alia Toro-Bahamonde; Rosario Costas-Muñiz; Guillermo N Armaiz-Peña; Heather Jim Journal: Nurs Rep Date: 2021-06-09
Authors: Keyla Vargas-Román; Emilia I De la Fuente-Solana; Jonathan Cortés-Martín; Juan Carlos Sánchez-García; Christian J González-Vargas; Lourdes Díaz-Rodríguez Journal: J Clin Med Date: 2022-06-14 Impact factor: 4.964